Stevens-Johnson Syndrome Induced by Vandetanib
Annals of Dermatology
;
: S343-S345, 2011.
Article
Dans Anglais
| WPRIM
| ID: wpr-165614
ABSTRACT
Vandetanib is a once-daily oral anticancer drug that selectively inhibits key signaling pathways in cancer by targeting vascular endothelial growth factor receptors, epidermal growth factor receptors tyrosine kinase, and rearranged during transfection-dependent tumor cell proliferation and survival. The most frequently reported adverse events attributed to vandetanib include diarrhea, elevated aminotransferase, asymptomatic corrected QT interval prolongation, and hypertension. Though a number of randomized, doubleblind studies, including cutaneous adverse events attributed to vandetanib, have been reported along with these general symptoms, no case of Stevens-Johnson syndrome (SJS) has been reported. This paper demonstrates a case of SJS induced by vandetanib.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Pipéridines
/
Quinazolines
/
Protein-tyrosine kinases
/
Syndrome de Stevens-Johnson
/
Carcinome pulmonaire non à petites cellules
/
Récepteurs aux facteurs de croissance endothéliale vasculaire
/
Prolifération cellulaire
/
Diarrhée
/
Récepteurs ErbB
/
Hypertension artérielle
Type d'étude:
Essai clinique contrôlé
langue:
Anglais
Texte intégral:
Annals of Dermatology
Année:
2011
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS